RadioGel is an yttrium-90 (90Y) based injectable Precision Radionuclide Therapy (PRnT) device
for the treatment of cancerous tumors in animals (IsoPet®) and humans (RadioGel™).
Precision Radionuclide Therapy (PRnT) uses highly localized radiation to destroy,
cancerous tumors by placing a radioactive isotope directly inside the treatment
area using the company’s proprietary hydrogel technology.
Radiogel™ is a hydrogel liquid containing tiny Yttrium-90 (90Y) phosphate microparticles that may be administered directly into a tumor.
The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.
The Isopet® Solutions division utilized university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. Testing on feline sarcoma at
the Washington State University was completed in 2018 and testing on canine soft tissue sarcomas at the University of Missouri was completed in 2019.
IsoPet® Therapy is readily available at The University of Missouri and select Regional Clinics.
( Mike Korenko, Sc. D. • CEO • President | January 11, 2023 Press Release )
Richland WA, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that the company filed a utility patent application on a range of particles for precision radionuclide therapy as a follow-up to its provisional patent filed on 1/15/2022. This patent was filed in the USA and internationally via the Patent Cooperation Treaty, PCT. This includes Canada, the European Union, Japan, Australia, Brazil, China, India, South Korea, and the Russian Eurasian (Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, and Turkmenistan).